Nintedanib With or Without Dextromethorphan for Lung Fibrosis
Part of Lungs & breathing clinical trials.
This trial tests whether adding dextromethorphan (a common cough medicine) to nintedanib (a lung-fibrosis drug) helps slow lung damage in people with idiopathic pulmonary fibrosis (IPF)—a condition where lung tissue becomes scarred and stiff. The study lasts 12 weeks plus one follow-up visit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 40 years old
- You have been diagnosed with idiopathic pulmonary fibrosis (IPF) using standard guidelines
- Your lung function tests show forced vital capacity (FVC) at least 45% of predicted and carbon monoxide diffusion between 30–80% of predicted
- You have had a high-resolution CT scan of your lungs within the past 12 months showing a specific scarring pattern called UIP
- You can commit to 12 weeks of treatment, weekly visits, and one follow-up week
- You are willing to use reliable birth control during the study and for 3 months after (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests whether taking quercetin, a natural supplement, can help people with fibrotic interstitial lung diseases (a group of conditions that cause scarring in the lungs). If you have been diagnosed with idiopathic pulmonary fibrosis (IPF) or another fibrotic ILD and are on standard treatments, you may be able to join.
This trial tests a new oral medication, HSK50042, for people with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help slow lung function decline, and is looking for patients who meet specific lung function criteria and are either not currently on anti-fibrotic therapy or on a stable dose.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.